Schrödinger, Inc. (SDGR)

NASDAQ: SDGR · Real-Time Price · USD
21.44
-0.08 (-0.37%)
At close: May 29, 2025, 4:00 PM
21.15
-0.29 (-1.35%)
After-hours: May 29, 2025, 7:59 PM EDT
-0.37%
Market Cap 1.57B
Revenue (ttm) 230.49M
Net Income (ttm) -192.21M
Shares Out 73.38M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 759,653
Open 21.71
Previous Close 21.52
Day's Range 21.25 - 22.00
52-Week Range 16.60 - 28.47
Beta 1.84
Analysts Buy
Price Target 32.80 (+52.99%)
Earnings Date May 7, 2025

About SDGR

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration an... [Read more]

Sector Healthcare
IPO Date Feb 6, 2020
Employees 891
Stock Exchange NASDAQ
Ticker Symbol SDGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price forecast is $32.8, which is an increase of 52.99% from the latest price.

Price Target
$32.8
(52.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global Head of Softwar...

7 hours ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

14 hours ago - Accesswire

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial off...

16 hours ago - Business Wire

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

1 day ago - CNBC Television

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

1 day ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

2 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

3 days ago - Accesswire

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

4 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

6 days ago - Accesswire

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 21, 2025, the company granted restricted stock units (RSUs) with respect to 7,051 shares of the company's common ...

6 days ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASD...

7 days ago - Accesswire

Schrödinger to Present at Jefferies Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation wil...

7 days ago - Business Wire

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, c...

9 days ago - Seeking Alpha

Schrödinger Announces CFO Appointment

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial off...

9 days ago - Business Wire

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hema...

15 days ago - Business Wire

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - ...

22 days ago - Seeking Alpha

Schrödinger Reports Strong First Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended March 31, 2025.

22 days ago - Business Wire

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation...

24 days ago - Business Wire

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AAC...

4 weeks ago - Business Wire

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close.

5 weeks ago - Business Wire

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing require...

6 weeks ago - Business Wire

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a pro...

6 weeks ago - Seeking Alpha

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025.

2 months ago - Business Wire

Schrödinger: Still Waiting On A Catalyst

Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the compan...

3 months ago - Seeking Alpha

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Fa...

3 months ago - Seeking Alpha